Acadia Healthcare to Participate in March Investor Conferences
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) announced its participation in three investor conferences in March 2026. The company will present at the Raymond James & Associates’ 47th Annual Institutional Investors Conference, the Leerink Partners 2026 Global Healthcare Conference, and the Barclays 28th Annual Global Healthcare Conference. Live webcasts and replays of these presentations will be available on Acadia's investor relations website.
Earnings Preview: Acadia Healthcare (ACHC) Q4 Earnings Expected to Decline
Acadia Healthcare (ACHC) is expected to report a year-over-year decline in Q4 2025 earnings despite higher revenues. The Zacks consensus estimate predicts quarterly earnings of $0.03 per share, a 95.3% decrease, with revenues of $798.67 million, up 3.2%. While the company's Earnings ESP suggests a potential beat, its Zacks Rank of #5 makes a definitive prediction difficult.
Acadia Healthcare (ACHC) to Release Earnings on Wednesday
Acadia Healthcare (ACHC) is scheduled to release its Q4 2025 earnings before market open on Wednesday, February 25th, with analysts forecasting earnings per share of $0.03 and revenue of $800.099 million. The stock is currently trading around $16.42, significantly below its 12-month high, and holds a consensus "Hold" rating from analysts with an average price target of $18.62. Institutional investors have shown mixed activity, with some increasing and others initiating positions in ACHC.
Public Sector Pension Investment Board Takes $8.92 Million Position in Acadia Healthcare Company, Inc. $ACHC
The Public Sector Pension Investment Board has taken a new position in Acadia Healthcare Company, Inc. (NASDAQ:ACHC), acquiring 360,234 shares valued at approximately $8.92 million. Other institutional investors, including Abrams Bison Investments LLC, Amundi, Qube Research & Technologies Ltd, Teca Partners LP, and Bank of America Corp DE, also adjusted their holdings in the company. Despite these investments, analysts have recently trimmed price targets, resulting in a consensus "Hold" rating and an average target price of $18.62 for Acadia Healthcare.
Short Interest in Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Increases By 20.0%
Short interest in Acadia Healthcare Company, Inc. (NASDAQ:ACHC) rose significantly by 20.0% in January, reaching 26,360,014 shares, representing 29.2% of the company's shares being short sold. Institutional investors like Goldman Sachs, Jefferies, Abrams Bison, Deerfield, and Rubric increased their stakes, with Goldman Sachs boosting its position by 417.8%. Analysts are mixed on ACHC, with a consensus "Hold" rating and an average price target of $18.62.
LSV Asset Management Purchases New Stake in Acadia Healthcare Company, Inc. $ACHC
LSV Asset Management recently acquired a new stake of 217,500 shares in Acadia Healthcare Company, Inc. (NASDAQ:ACHC), valued at approximately $5.385 million. This purchase represents about 0.24% of the company. Acadia Healthcare currently holds a consensus "Hold" rating from analysts with an average price target of $18.62, while the stock trades near its 52-week low.
A Look At Acadia Healthcare (ACHC) Valuation After David Einhorn Stake And Leadership Changes
Acadia Healthcare (ACHC) has come into focus following David Einhorn's stake disclosure and recent leadership changes, with its stock showing strong short-term rebounds despite prior declines. The company is currently considered undervalued with a fair value of $19.07 per share, driven by anticipated growth from facility development and joint ventures. However, potential challenges like Medicaid volume pressure and higher bad debt expenses could impact this positive outlook.
A Look At Acadia Healthcare (ACHC) Valuation After David Einhorn Stake And Leadership Changes
Acadia Healthcare (ACHC) has seen renewed interest following hedge fund manager David Einhorn's disclosed stake and recent leadership changes, leading to a sharp short-term rebound in its stock. Despite a significant one-year decline, the stock is currently trading at a 13.72% discount to the average analyst target of $19.07, suggesting it might be undervalued. The company's expansion plans, including accelerated facility development and joint ventures, are expected to drive future growth, though potential risks like Medicaid volume pressure and higher bad debt expense could challenge the valuation.
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know
Shares of Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health surged following a softer-than-expected January Consumer Price Index report, which increased hopes for Federal Reserve interest rate cuts as early as June. The market responded positively to the inflation data, with analysts noting that lower inflation is a key factor enabling the central bank to ease its monetary policy, which generally supports stock valuations. RadNet, in particular, saw a 6.5% jump, with its shares being somewhat volatile over the past year.
The Market Lifts Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Shares 27% But It Can Do More
Acadia Healthcare Company's shares have risen 27% in the last month, but are still down 62% over the past year. The company's P/E ratio of 13.7x is lower than the market average of 20x, indicating potential undervaluation despite a recent decline in earnings. Analysts, however, forecast a 24% annual EPS growth for Acadia Healthcare Company for the next three years, significantly higher than the broader market's 12% forecast.
Investors Still Aren't Entirely Convinced By Acadia Healthcare Company, Inc.'s (NASDAQ:ACHC) Earnings Despite 27% Price Jump
Acadia Healthcare Company's shares have jumped 27% recently, but investors remain unconvinced due to a 62% decline over the last year and poor earnings performance. Despite analysts forecasting 24% annual growth, higher than the broader market, the company's P/E ratio remains low, suggesting shareholder skepticism about future stability or unobserved threats to earnings. The article advises caution, highlighting that the low P/E might be justified by underlying issues despite the positive growth outlook.
Investors Still Aren't Entirely Convinced By Acadia Healthcare Company, Inc.'s (NASDAQ:ACHC) Earnings Despite 27% Price Jump
Acadia Healthcare Company's (ACHC) shares rebounded 27% in the last month, but the stock is still down 62% over the past year. Despite a low P/E ratio of 13.7x and analyst forecasts of 24% annual growth, significantly higher than the broader market, investors remain unconvinced, likely due to recent declining earnings. The article suggests there might be unobserved threats to earnings keeping the P/E low, despite the positive outlook.
Acadia Healthcare $179M Securities Class Action Settlement
Acadia Healthcare has agreed to a $179 million securities class action settlement for investors who purchased stock between April 30, 2014, and November 15, 2018. The lawsuit alleged the company made false statements regarding care quality, staffing, regulatory compliance, and UK operations' financial performance. Eligible class members can file an online or mailed claim by April 30, 2026, and payouts will depend on individual losses and the total number of valid claims.
(ACHC) Risk Channels and Responsive Allocation
The article analyzes Acadia Healthcare Company Inc. (NASDAQ: ACHC), noting a strong near-term sentiment that contrasts with persistent mid and long-term weakness. It highlights an exceptional 105.8:1 risk-reward setup, targeting a 30.5% gain versus 0.3% risk. The analysis includes three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles.
Acadia Healthcare Welcomes New Leadership with CEO Debra Osteen’s Appointment
Acadia Healthcare's stock surged by 12.74% following the appointment of Debra Osteen as CEO and the reaffirmation of full-year 2025 financial guidance. The company, a leader in behavioral healthcare, is navigating challenges such as Medicaid policy changes, but its strong financial standing and strategic leadership aim to maintain stability and pursue growth. A proposed $179 million settlement in a securities litigation case also contributes to a clearer path forward for the company.
A Look At Acadia Healthcare (ACHC) Valuation As Capex Cuts And Activist Pressure Spark Turnaround Hopes
Acadia Healthcare (ACHC) is gaining investor attention after cutting 2026 capital expenditures and facing pressure from activist shareholder Engine Capital for strategic review. Despite recent share price declines, the company's fair value is estimated at $19.07 against a current $13.55, suggesting it may be undervalued. The turnaround narrative hinges on capital discipline, reduced costs, and improved free cash flow generation.
Acadia Healthcare Announces Date for Fourth Quarter and Year-End 2025 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) announced it will release its fourth quarter and year-end 2025 results on Wednesday, February 25, 2026, before the market opens. Following the release, the company will conduct a conference call with institutional investors and analysts at 9:00 a.m. ET on the same day. A live webcast of the call will be available on Acadia Healthcare's website in the "Investors" section.
Acadia Healthcare (BIT:1ACHC) Price Target Decreased by 11.12% to 16.86
Acadia Healthcare's (BIT:1ACHC) average one-year price target has been decreased by 11.12% to €16.86 per share, down from €18.97. This new target represents a potential 54.71% increase from its last closing price. Institutional ownership in Acadia Healthcare has also seen shifts, with major funds like Wellington Management Group Llp and Khrom Capital Management increasing their positions.
Acadia Healthcare Leadership Reset And Activist Pressure Refocus Investor Attention
Acadia Healthcare Company reappointed Debra K. Osteen as CEO following Christopher H. Hunter's departure, while activist investor Engine Capital is pressing for a strategic review, including a potential sale or share buybacks. This leadership change and activist pressure come amidst a significant stock decline, with shares trading at $13.21, down substantially over the past three years. Investors are now watching closely to see how the board will respond to the demands and what actions will be taken to improve returns and address operational concerns.
Acadia Healthcare Leadership Reset And Activist Pressure Refocus Investor Attention
Acadia Healthcare (NASDAQ:ACHC) has reappointed Debra K. Osteen as CEO following the departure of Christopher H. Hunter, amidst activist investor Engine Capital's call for a strategic review including a potential sale or significant share buybacks. The company's stock has seen substantial declines, dropping 70.5% over the past year and 83.5% over three years, intensifying pressure on the board to improve returns. Osteen's return, coupled with activist involvement, suggests a focus on operational stability and strategic actions to address financial performance.
Acadia Healthcare Company, Inc. (ACHC): A Bull Case Theory
This article summarizes a bullish thesis on Acadia Healthcare Company, Inc. (ACHC), presenting it as a deep-value opportunity at distressed levels. Key drivers for potential upside include management's capex cuts leading to positive free cash flow, potential activist investor influence for strategic changes, and the resilience of the psychiatric facility industry despite legal risks. The stock is seen as an attractive "sin stock" with substantial upside and limited near-term downside.
Acadia Healthcare appoints Debbie Osteen as CEO, confirms 2025 outlook
Acadia Healthcare has announced the appointment of Debbie Osteen as its new Chief Executive Officer. The company also confirmed its financial outlook for 2025. These announcements indicate new leadership and a reaffirmed financial direction for Acadia Healthcare.
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) Receives Average Recommendation of "Hold" from Analysts
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) has received a consensus "Hold" rating from fifteen research firms, with an average one-year price target of $18.62. Despite some buy ratings, several major brokers have recently trimmed their price targets, indicating mixed analyst sentiment. ACHC's stock currently trades around $13.44, with a market capitalization of $1.24 billion and a P/E ratio of 11.49, while the company reported Q3 earnings of $0.72 per share, beating estimates by $0.01.
A Look At Acadia Healthcare Company (ACHC) Valuation After CEO Transition Back To Debra K. Osteen
Acadia Healthcare Company (ACHC) has seen its former CEO, Debra K. Osteen, return amidst a significant share price decline, raising questions about its valuation. Despite negative returns, the company is considered "heavily discounted" with a narrative fair value of $25.32, driven by expected growth from facility development and expansion. The article suggests this leadership change could be a reset opportunity for investors, encouraging further research into the company's financial outlook and the broader healthcare sector.
A Look At Acadia Healthcare Company (ACHC) Valuation After CEO Transition Back To Debra K. Osteen
Acadia Healthcare Company (ACHC) has reappointed former CEO Debra K. Osteen, a move that follows significant stock decline. Despite this, the company is considered heavily undervalued at $13.48 compared to a $25.32 fair value, driven by expected multiyear growth from facility expansion and joint ventures. However, this optimistic outlook is balanced by ongoing legal and regulatory concerns and the need for Medicaid volume stabilization.
Does Acadia Healthcare (ACHC) Leadership Shuffle Clarify Its Long‑Term Strategy Or Cloud It Further?
Acadia Healthcare (ACHC) recently saw its former CEO, Debra K. Osteen, return to lead the company after Christopher H. Hunter stepped down, effective January 20, 2026. This leadership change brings a seasoned behavioral health operator back into the top role, potentially stabilizing investor perception despite the company's past earnings pressure and weak share price performance. The main issues remain compressed margins, low return on equity, and debt not well covered by operating cash flow, with Osteen's return seen as a test to address these challenges with experienced leadership.
Does Acadia Healthcare (ACHC) Leadership Shuffle Clarify Its Long‑Term Strategy Or Cloud It Further?
Acadia Healthcare recently saw former CEO Debra K. Osteen return to lead the company after Christopher H. Hunter stepped down. This leadership change aims to address ongoing challenges like compressed margins, low return on equity, and debt coverage issues. While Osteen's return could provide a short-term catalyst due to her experience, the article questions whether this will truly clarify or further cloud the company's long-term strategy amidst varied investor perspectives on its valuation.
Acadia Healthcare CEO Christopher Hunter departs, separation agreement disclosed
Acadia Healthcare has announced the departure of CEO Christopher H. Hunter, effective immediately. Hunter will receive various separation benefits, including his 2025 annual bonus eligibility, a payment equal to 1.5 times his base salary and target bonus, and a lump sum cash payment of $1,785,000. This news follows other recent developments for Acadia, including the return of former CEO Debra K. Osteen and stock downgrades from Jefferies, TD Cowen, and RBC Capital due to operational and macro-economic headwinds.
Acadia Healthcare CEO Christopher Hunter departs, separation agreement disclosed By Investing.com
Acadia Healthcare Company, Inc. announced the departure of CEO Christopher H. Hunter, effective January 20th. Hunter's separation agreement includes eligibility for his 2025 annual bonus, a payment equal to 1.5 times his base salary and target bonus, and continued health benefits. A prorated portion of his performance-based restricted stock units remains eligible to vest, while other unvested equity awards were forfeited, with these benefits contingent on a general release of claims.
Filing reveals terms of former CEO Christopher Hunter's split from Acadia Healthcare
Acadia Healthcare's former CEO, Christopher Hunter, was ousted on January 20th, 2026. This article previews the details of his compensation package, which includes a substantial retention bonus tied to his continued employment during government investigations.
Lobbying Update: $30,000 of ACADIA HEALTHCARE COMPANY INC. lobbying was just disclosed
ACADIA HEALTHCARE COMPANY INC. (ACHC) disclosed $30,000 in lobbying expenditures for Q4 2025, focusing on healthcare and regulatory issues. The article also details recent hedge fund activity, with 137 institutional investors adding shares and 166 decreasing positions, and provides a summary of recent analyst ratings, predominantly "Buy" or "Outperform," with a median price target of $18.5 from 14 analysts.
Big News: Debra K Osteen Adds $2.45M In Acadia Healthcare Co Stock Options Io Portfolio
Debra K. Osteen, CEO of Acadia Healthcare Co (NASDAQ: ACHC), recently acquired stock options for 1,125,000 shares, valued at approximately $2.45 million, as reported in an SEC filing. This insider activity indicates positive anticipation for the stock's future performance. The article also provides a financial overview of Acadia Healthcare Co, highlighting its revenue growth, profitability metrics, debt management, and market valuation.
Acadia Healthcare (NASDAQ:ACHC) Shares Gap Down - Should You Sell?
Acadia Healthcare (NASDAQ:ACHC) experienced a share price gap down before trading on Thursday, though it saw an intraday rebound. Analysts currently hold a consensus "Hold" rating for the stock, with varied price targets and some recent downgrades. The company's recent earnings beat estimates, but revenue slightly missed expectations, and its stock performance shows the 50-day simple moving average below the 200-day simple moving average.
ACHC Downgraded by Jefferies with Substantial Price Target Cut
Jefferies has downgraded Acadia Healthcare Co (ACHC) from 'Buy' to 'Hold', drastically cutting its price target from $34.00 to $15.00, a 55.88% decrease. This downgrade is part of a trend of reduced price targets from various analysts amid changing perceptions in the healthcare sector. Despite the downgrades, the average analyst target price of $19.50 still implies a 35.79% upside from the current price, with GuruFocus estimating an even larger potential upside based on its GF Value.
Acadia Healthcare rehires former CEO amid financial, legal challenges
Acadia Healthcare has rehired its former CEO, Debra Osteen, amidst a period of declining stock price and increased litigation costs. Osteen, who previously served as CEO from December 2018 to March 2022, is taking over from Chris Hunter, who began his tenure in April 2022. The company has faced significant legal challenges, including settlements for alleged False Claims Act violations and claims of misleading investors, which have negatively impacted its financial performance.
Acadia Healthcare names former CEO Osteen to lead company again
Acadia Healthcare has reappointed Debra K. Osteen as CEO to address significant challenges, including a 73% stock drop over the past year and substantial macro headwinds. Osteen, who previously led Acadia from 2018 to 2022, returns as the company grapples with a $2.45 billion debt burden and negative free cash flow. Despite these issues and recent downgrades from analysts, the company reaffirmed its 2025 financial guidance and analysts predict profitability for the year.
Is Acadia Healthcare (ACHC) Now Attractive After Steep Multi‑Year Share Price Declines
Acadia Healthcare (ACHC) has seen significant share price declines over multiple years, but a recent analysis suggests the stock may be undervalued. A Discounted Cash Flow (DCF) model indicates a 95.4% undervaluation, while its P/E ratio is also below both the sector average and its tailored "Fair Ratio." Investors are encouraged to explore different "Narratives" on the platform to form their own valuation based on individual assumptions.
Acadia Healthcare Stock (+22%): CEO Return Sparks Mechanical Re-Rate
Acadia Healthcare's stock rose by 22% due to a mechanical re-rate, sparked by the return of its CEO. This article from Trefis discusses the implications of this event on the company's valuation and market perception.
Why Acadia Healthcare (ACHC) Stock Is Up Today
Acadia Healthcare (ACHC) stock surged by 24% after the company announced the re-appointment of former CEO Debra K. Osteen, known for her successful turnaround of the business, which had previously led to a near 100% stock increase. Investors reacted positively to her return, and Acadia also reaffirmed its full-year 2025 financial guidance, signaling stability despite the leadership change. This positive news follows a recent stock drop attributed to a new Medicaid policy impacting the company's financial outlook.
Acadia Healthcare (ACHC) Appoints Debra Osteen as New CEO
Acadia Healthcare (ACHC) has appointed Debra Osteen as its new Chief Executive Officer, effective immediately. Osteen, who previously served as CEO and a board member, replaces Chris Hunter. The company, which specializes in behavioral healthcare facilities, faces financial challenges including a distressed Altman Z-Score and significant debt, despite potential undervaluation and cautiously optimistic analyst sentiment.
Acadia Healthcare Appoints Debbie Osteen As Chief Executive Officer
Acadia Healthcare has announced the appointment of Debbie Osteen as its new Chief Executive Officer. This leadership change is a significant development for the company. The news was reported by Reuters and is of interest to those following ACHC management.
Acadia Healthcare Appoints Debbie Osteen as Chief Executive Officer
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) has announced the appointment of Debra K. Osteen as CEO, effective immediately, succeeding Chris Hunter. Osteen, a former CEO and Board member, will also rejoin the Board while the company conducts a search for a long-term successor. Acadia Healthcare reaffirmed its full-year 2025 financial guidance, expecting revenue between $3.28 billion and $3.30 billion, and adjusted EBITDA between $601 million and $611 million.
(ACHC) Acadia Healthcare Expects 2025 Revenue Range $3.28B to $3.30B, vs. FactSet Est of $3.29B
Acadia Healthcare Company, Inc. (ACHC) expects its 2025 revenue to be in the range of $3.28 billion to $3.30 billion. This forecast aligns closely with the FactSet estimate of $3.29 billion. The announcement was made on January 20, 2026, and also included news of new CEO appointment and reaffirmation of adjusted EPS guidance.
A Look At Acadia Healthcare (ACHC) Valuation After New York Medicaid Reimbursement Policy Shift
Acadia Healthcare (ACHC) is facing an estimated US$25-30 million EBITDA headwind due to a New York Medicaid policy change affecting out-of-state reimbursements. The company's stock has seen a significant decline, leading to questions about whether its current trading price of US$11.68 reflects temporary pressures or the market's expectation of future recovery, especially given a narrative fair value of US$25.32. Analysts have a consensus target of $30.429, though opinions vary widely.
A Look At Acadia Healthcare (ACHC) Valuation After New York Medicaid Reimbursement Policy Shift
Acadia Healthcare (ACHC) is facing a valuation reassessment after a new New York Medicaid policy is expected to reduce reimbursements by $25M-$30M. This news coincides with a significant share price decline, leading investors to question if the current trading price around US$11.68 reflects market concerns or ongoing recovery potential. Despite analysts' consensus price target of $30.429, the article suggests the company remains undervalued at $25.32 based on its narrative fair value, but warns of risks from softer Medicaid volumes and ongoing costs.
TD Cowen Lowers Acadia Healthcare (NASDAQ:ACHC) Price Target to $22.00
TD Cowen has lowered its price target for Acadia Healthcare (NASDAQ:ACHC) to $22.00 from $25.00, while maintaining a "buy" rating, indicating a potential upside of 89.04%. Despite this, other firms have trimmed ratings, leading to a MarketBeat consensus of "Hold" with an average price target of $18.92. Acadia Healthcare's stock recently traded down by 2.3% to $11.64, following a quarter with a slight EPS beat and setting FY 2025 guidance.
Acadia Healthcare (ACHC) Is Down 14.4% After New York Medicaid Shift Tightens Out-of-State Reimbursement
Acadia Healthcare (ACHC) experienced a 14.4% drop after a New York Medicaid policy change tightened reimbursement for out-of-state behavioral health care, creating a US$25 million to US$30 million EBITDA headwind. Despite this, Acadia reiterated its 2025 revenue guidance of US$3.28 billion to US$3.30 billion, suggesting a contained immediate top-line impact. This highlights the company's sensitivity to state-level Medicaid decisions and concerns about future earnings and investor confidence.
Why Acadia Healthcare (ACHC) Shares Are Getting Obliterated Today
Acadia Healthcare (ACHC) shares dropped 6.4% after the company announced a new New York Medicaid policy restricting out-of-state reimbursement would create a $25-30 million headwind to its EBITDA, leading RBC Capital to cut its price target. This negative momentum follows an earlier drop when the policy's impact was first disclosed. Despite recent industry optimism, ACHC is down significantly year-to-date and from its 52-week high.
Acadia Healthcare (NASDAQ:ACHC) Trading Down 6.5% After Analyst Downgrade
Acadia Healthcare (NASDAQ:ACHC) shares dropped 6.5% after Royal Bank of Canada and other firms lowered price targets and ratings, with Bank of America downgrading the stock to "underperform." The company reported a slight EPS beat for the last quarter but missed revenue expectations and provided FY2025 EPS guidance. Despite a MarketBeat consensus of "Hold" with an average price target of $18.64, the stock experienced significant trading volume.
Acadia Healthcare Co Stock: A Deep Dive Into Analyst Perspectives (16 Ratings)
In the last three months, 16 analysts have evaluated Acadia Healthcare Co (NASDAQ: ACHC), providing a range of perspectives. The average 12-month price target is set at $20.38, a 19.98% decrease from the previous average. Despite its smaller market capitalization and lower revenue growth compared to peers, Acadia Healthcare Co demonstrates strong financial health with impressive net margin, return on equity, and return on assets.
